Literature DB >> 25836932

Nonurothelial bladder cancer and rare variant histologies.

Daniel Willis1, Ashish M Kamat2.   

Abstract

At present, radical cystectomy is a mainstay in the management of all bladder cancers, whether of conventional urothelial histology or variant. However, in the case of some variants, it is clearly not enough and multimodal therapy is an imperative. In other cases, systemic therapy might be ineffective or even detrimental if it leads to delay in surgery (ie, squamous cell carcinoma). Thus, identification of variant histology is a critical part of bladder cancer staging because such histology may require appropriately tailored therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Micropapillary bladder cancer; Radical cystectomy; Treatment guidelines; Urothelial carcinoma; Variant histology

Mesh:

Year:  2015        PMID: 25836932     DOI: 10.1016/j.hoc.2014.10.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  20 in total

Review 1.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

2.  The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.

Authors:  Qiang Li; Melissa Assel; Nicole E Benfante; Eugene J Pietzak; Harry W Herr; Machele Donat; Eugene K Cha; Timothy F Donahue; Bernard H Bochner; Guido Dalbagni
Journal:  Eur Urol Focus       Date:  2017-06-27

Review 3.  The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.

Authors:  Michael Rink; Heidi Schwarzenbach; Sabine Riethdorf; Armin Soave
Journal:  World J Urol       Date:  2018-10-26       Impact factor: 4.226

Review 4.  Molecular and histopathology directed therapy for advanced bladder cancer.

Authors:  Constantine Alifrangis; Ursula McGovern; Alex Freeman; Thomas Powles; Mark Linch
Journal:  Nat Rev Urol       Date:  2019-07-09       Impact factor: 14.432

5.  The association between variant urothelial histologies, pathological stage and disease specific survival in patients with bladder cancer.

Authors:  Abubekir Böyük; Öner Şanlı; Selçuk Erdem; Tzevat Tefik; Faruk Özcan; Yasemin Özlük; Işın Kılıçarslan; Murat Tunç
Journal:  Turk J Urol       Date:  2017-12-19

6.  Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?

Authors:  Kevin Lm Chua; Grace Kusumawidjaja; Jure Murgic; Melvin Lk Chua
Journal:  ESMO Open       Date:  2017-03-07

Review 7.  Imaging and Management of Bladder Cancer.

Authors:  Vincenzo K Wong; Dhakshinamoorthy Ganeshan; Corey T Jensen; Catherine E Devine
Journal:  Cancers (Basel)       Date:  2021-03-19       Impact factor: 6.639

8.  Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study.

Authors:  Nicolas Epaillard; Pauline Parent; Yohann Loriot; Pernelle Lavaud; E-B Vera-Cea; Nieves Martinez-Chanza; Alejo Rodriguez-Vida; Clement Dumont; Rebeca Lozano; Casilda Llácer; Raffaele Ratta; Stephane Oudard; Constance Thibault; Edouard Auclin
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

9.  Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.

Authors:  Chaozheng Zhou; Anqi Lin; Manming Cao; Weimin Ding; Weiming Mou; Ningyi Guo; Zhenyu Chen; Jian Zhang; Peng Luo
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

10.  Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer.

Authors:  Zhao Cai; Huang Chen; Jingqiao Bai; Yang Zheng; Jianhui Ma; Xiongwei Cai; Yu Liu; Kaitai Zhang; Jianzhong Shou; Yanning Gao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.